Rankings / Cognitive — Prescription Stimulants
Mazindol ER (Quilience)
Cognitive · Wakefulness / non-amphetamine stimulant (narcolepsy, ADHD)
Tier C+
Bottom line
Read Off Label grades Mazindol ER (Quilience) as C+ (5.5/10) based on moderate evidence, moderate benefit magnitude, and a med-risk safety profile.
NLS Pharmaceutics is reviving mazindol — a 1970s anorectic stimulant — as an extended-release drug (Quilience) for narcolepsy and ADHD.
Typical use: Oral once daily, extended-release (Phase 2/3 dosing) — Investigational.
What this is
NLS Pharmaceutics is reviving mazindol — a 1970s anorectic stimulant — as an extended-release drug (Quilience) for narcolepsy and ADHD. Its mix of dopamine/norepinephrine reuptake inhibition plus partial orexin agonism makes it an unusual non-amphetamine wakefulness/attention agent. The Phase 2 ADHD trial met all primary and secondary endpoints and the FDA cleared the Phase 3 AMAZE narcolepsy program. Another stimulant-alternative to watch, though the orexin agonists (oveporexton) are further along for narcolepsy. Industry-sponsored; pivotal data pending.
Mechanism
Tricyclic agent that inhibits dopamine and norepinephrine reuptake and has partial orexin-receptor agonism; an extended-release reformulation aimed at narcolepsy and ADHD with a smoother profile than classic stimulants
Dose & route
Oral once daily, extended-release (Phase 2/3 dosing)
Citations
- https://www.clinicaltrialsarena.com/news/fda-nls-narcolepsy-phase-iii/
- https://www.psychiatrictimes.com/view/positive-data-for-narcolepsy-sleep-disorders-adhd-drug
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Mazindol ER (Quilience) work?
- Read Off Label rates the evidence for Mazindol ER (Quilience) as Moderate and the benefit magnitude as moderate, producing an overall grade of C+ (5.5/10). NLS Pharmaceutics is reviving mazindol — a 1970s anorectic stimulant — as an extended-release drug (Quilience) for narcolepsy and ADHD.
- Is Mazindol ER (Quilience) safe?
- Mazindol ER (Quilience) has a med risk profile in published human data. Legal status: Investigational (NLS Pharmaceutics; FDA-cleared Phase 3 narcolepsy program; mazindol was a withdrawn anorectic drug). This is not medical advice — see the disclaimer.
- What is the typical dose for Mazindol ER (Quilience)?
- Oral once daily, extended-release (Phase 2/3 dosing)
- How does Mazindol ER (Quilience) work?
- Tricyclic agent that inhibits dopamine and norepinephrine reuptake and has partial orexin-receptor agonism; an extended-release reformulation aimed at narcolepsy and ADHD with a smoother profile than classic stimulants
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.